Prostate cancer & PSA testing

What this page helps with

PSA (prostate-specific antigen) is a blood test. This page helps you prepare for a conversation with a provider about whether testing is right for you. It does not recommend for or against testing, does not interpret results and does not set a cut-off; those belong with your clinician.

Who the discussion is for, and who needs another pathway

Canadian recommendations differ. The Canadian Urological Association (2022) supports informed, individualized consideration of PSA testing for suitable people who elect it, generally from age 50, or from 45 with increased risk. The Canadian Task Force on Preventive Health Care's published guideline (2014, not since updated) recommends against PSA screening, with different strength by age. The Canadian Cancer Society supports an informed discussion. Ontario's Ministry of Health advises against mass screening and offers information to support an informed decision. These are not a unanimous recommendation to screen — the choice is yours, made with a provider.

Increased risk in Canadian urology guidance means a first-degree relative with prostate cancer, African ancestry, or a known hereditary risk such as a BRCA variant. A known hereditary risk or a clinician-assessed strong family pattern may merit genetics or specialist assessment; a broad family history of other cancers does not establish a hereditary syndrome, and worry alone is a preference rather than a risk factor.

Stopping. Routine PSA screening is generally stopped around 70, or when life expectancy is under about 10 years, because benefit becomes less likely to outweigh harm; decisions can still be individualized. This applies to screening in people without symptoms.

Not routine screening. Symptoms need assessment. Diagnosed prostate cancer, active surveillance, post-treatment follow-up, or an abnormal PSA awaiting assessment are monitoring or diagnosis — directed by your treating clinician and not affected by any screening stopping age. Stopping population screening is not stopping cancer monitoring.

How to access it in Ontario

A family doctor or nurse practitioner orders the test. In Ontario, a PSA test done purely for asymptomatic screening is generally not OHIP-insured and the laboratory usually charges a fee; the test is insured when a physician or nurse practitioner suspects prostate cancer (family history, race, examination findings or symptoms) or is monitoring diagnosed prostate cancer (Ministry requisition wording effective April 16, 2026). Whether a particular risk factor makes your test insured is decided by the ordering clinician — confirm with them or the lab; this site does not quote a price. Without a provider, Health811 (811) or Health Care Connect (1-888-579-6707) can help you find one.

Potential benefits and limitations

Screening may find some cancers earlier, and for some people that reduces the chance of dying from prostate cancer. Limitations are real: false positives (a raised PSA with no cancer) leading to biopsies with their own risks; false negatives (a normal PSA does not prove there is no cancer); and overdiagnosis — finding slow-growing cancers that would never have caused symptoms, with treatment side effects such as urinary and sexual problems. Older summaries quote fixed percentages for these; they depend on the population and era studied, so ask your provider what applies to you rather than relying on a single number.

Things that affect a PSA result. Some situations raise PSA without cancer (an enlarged prostate, prostate infection, a recent procedure). Some medications and hormones can lower measured PSA, which affects interpretation. Tell your clinician about all medications and hormones; do not stop them on your own.

What the test involves

A simple blood draw. Your clinician may also discuss a physical examination. Results are interpreted in context — age, prostate size, prior results and medications — by the clinician, not by a single universal number.

What happens after an abnormal result

An elevated PSA is usually followed by a repeat test and a clinical review. Depending on the picture, next steps may include imaging (MRI) or referral to a urologist, and sometimes a biopsy. Many raised results are not cancer. This page cannot interpret your result.

Questions to ask your provider

• Given my age and risk factors, how do the benefits and harms of testing balance for me?
• Would the test be OHIP-insured in my situation?
• Do any of my medications or hormones affect the result?
• If the result is raised, what would happen next?
• At what point would we stop routine testing?

PSA conversation guide

Sources and when they were checked

• R14 — UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis, CUAJ 2022;16(4):E184–E196. Checked for superseding CUA publications 2026-09-15: none found.
• R15 — Prostate cancer (2014 guideline), Canadian Task Force on Preventive Health Care.
• R16 — Prostate-specific antigen (PSA) test, Canadian Cancer Society.
• R17 — Bulletin 260405 — Revision to PSA test on lab requisition effective April 16, 2026, Ontario Ministry of Health.

Sources checked 2026-09-15. Page built 2026-09-15. Independent qualified clinical review: not yet completed. Found a problem? How to report a correction.